Drug-drug interaction study of repaglinide with regard to CYP2C8 and OATP1B1
Not Applicable
- Conditions
- healthy male and female
- Registration Number
- JPRN-UMIN000015430
- Lead Sponsor
- Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
The investigators must ensure that all subjects being considered meet the ollowing exclusion criteria or conditions: 1) history of allergy to any drugs 2) medical attention within 2 months prior to participation 3) donation of 200 mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 4) donation of 400 mL or more of blood within 12 weeks prior to participation 5) recent (past 4 months) participation in other clinical trial for investigational new chemical entity 6) history of drug abuse 7) alcohol abuse 8) lactose intolerant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetics of substrate cocktail (repaglinide, pitavastatin and pioglitazone)
- Secondary Outcome Measures
Name Time Method